myriad_S_stacked.png
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
September 18, 2023 08:00 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Memorial Sloan...
myriad_S_stacked.png
Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work
September 06, 2023 16:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Great Place To Work® and Fortune magazine...
myriad_S_stacked.png
New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women
September 06, 2023 07:00 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today revealed new nationwide survey results indicating...
myriad_S_stacked.png
Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference
September 05, 2023 08:00 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced management will participate in the...
myriad_S_stacked.png
Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk
August 22, 2023 09:00 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Onsite Women’s Health, a leading national provider of...
myriad_S_stacked.png
Myriad Genetics to Host Investor Day on September 19, 2023
August 17, 2023 16:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Day at the newly constructed Dr....
myriad_S_stacked.png
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
August 15, 2023 07:05 ET | Myriad Genetics, Inc.
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.,...
myriad_S_stacked.png
Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment
August 08, 2023 16:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Intermountain Precision Genomics, part of the...
myriad_S_stacked.png
Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status
August 07, 2023 16:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced enhancements to the GeneSight® Psychotropic test,...
myriad_S_stacked.png
Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth
August 03, 2023 16:05 ET | Myriad Genetics, Inc.
Highlights: Second quarter testing volume grew 17% year-over-year, excluding contributions from the SneakPeek® Early Gender DNA Test.In the second quarter: Hereditary cancer test volumes grew 20%...